Core Insights - The company reported total net revenue of $15.2 million for the fiscal 2026 second quarter [1] - Adjusted EBITDA was $(0.8) million, which includes investments of $30.0 million for the launch of EXXUA [1] - The company launched EXXUA™ (gepirone) extended-release tablets in December 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] Financial Performance - Total net revenue for the quarter was $15.2 million [1] - Adjusted EBITDA was negative at $(0.8) million, reflecting the costs associated with the EXXUA launch [1] - The company had a cash balance of $30.0 million as of December 31, 2025 [1] Product Launch - EXXUA™ (gepirone) was launched in December 2025 as a key component of the company's commercial strategy [1] - The product aims to penetrate the significant U.S. market for major depressive disorder, valued at over $22 billion [1] Upcoming Events - The company will host a conference call and webcast on February 3, 2026, at 4:30 p.m. Eastern time to discuss the results [1]

Core Insights - The company reported total net revenue of $13.9 million and a net income of $2.0 million, equating to $0.21 net income per share basic [1] - Adjusted EBITDA was $(0.6) million, which includes investments related to the launch of EXXUA [1] - The company has a cash balance of $32.6 million as of September 30, 2025 [1] - The launch of EXXUA (gepirone) extended-release tablets is on track for the fourth calendar quarter of 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] - A conference call and webcast is scheduled for November 13, 2025, at 4:30 p.m. Eastern time [1]